Ligand Pharmaceuticals Equity 2024

Ligand Pharmaceuticals Aktienanalyse

What does Ligand Pharmaceuticals do?

Ligand Pharmaceuticals Inc is an American company that has been operating in the biotechnology industry for over 30 years. It was founded in 1987 in San Diego, California and has since built an impressive track record. The business model of Ligand Pharmaceuticals Inc is based on the development and commercialization of innovative drugs and technologies for the pharmaceutical and biotechnology industry. The company is a leading provider of resources for drug discovery and development, including ligand design, synthesis and analysis, tools for drug screening, and technologies for therapy optimization. Ligand Pharmaceuticals Inc is divided into several business segments that focus on different industries and categories of medication. These include oncology, immunology, neurology, metabolic diseases, and rare diseases. One of the key areas of Ligand Pharmaceuticals Inc is oncology, which focuses on the development of cancer drugs. The company currently has several innovative drugs in the pipeline targeting various types of cancer and showing promising results in clinical trials. Another important area of Ligand Pharmaceuticals Inc is immunology, which focuses on the development of drugs for autoimmune diseases. The company has some promising partnerships in this field, including one with Bristol Myers Squibb for the joint development of antibodies against the CTLA-4 receptor. In addition to drug development, Ligand Pharmaceuticals Inc also offers various technologies and tools for drug screening and therapy optimization. These include platforms for antibody and small molecule discovery, as well as technologies for antibody manufacturing and genome editing. Another important aspect of Ligand Pharmaceuticals Inc's business model is its partnership with other pharmaceutical companies. The company heavily relies on collaboration and currently has several strategic partnerships with some of the world's largest pharmaceutical companies. These partnerships allow Ligand to provide its partners with access to its technology and drug candidates, thereby expanding its portfolio. Over the years, Ligand Pharmaceuticals Inc has brought many successful products and technologies to the market. Some of the most well-known and successful products include Kyprolis, a treatment for multiple myeloma, and Promacta, a medication for immune thrombocytopenia. Overall, Ligand Pharmaceuticals Inc has built an impressive track record and is now considered one of the leading providers of resources for drug discovery and development. The company continues to prioritize collaboration and innovation and will undoubtedly bring many more innovative products and technologies to the market in the future. Ligand Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Ligand Pharmaceuticals's Equity

Ligand Pharmaceuticals's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Ligand Pharmaceuticals's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Ligand Pharmaceuticals's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Ligand Pharmaceuticals's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Ligand Pharmaceuticals’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Ligand Pharmaceuticals stock

What is the equity of Ligand Pharmaceuticals this year?

Ligand Pharmaceuticals has equity of 700.91 M USD this year.

What was the equity of Ligand Pharmaceuticals compared to the previous year?

The equity of Ligand Pharmaceuticals has increased/decreased by 17.31% increased compared to the previous year.

What impact does a high equity have on investors of Ligand Pharmaceuticals?

A high equity is advantageous for investors of Ligand Pharmaceuticals as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Ligand Pharmaceuticals?

A low equity can be a risk for investors of Ligand Pharmaceuticals, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Ligand Pharmaceuticals affect the company?

An increase in equity of Ligand Pharmaceuticals can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Ligand Pharmaceuticals affect the company?

A reduction in equity of Ligand Pharmaceuticals can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Ligand Pharmaceuticals?

Some factors that can affect the equity of Ligand Pharmaceuticals include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Ligand Pharmaceuticals so important for investors?

The equity of Ligand Pharmaceuticals is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Ligand Pharmaceuticals take to change the equity?

To change equity, Ligand Pharmaceuticals can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Ligand Pharmaceuticals pay?

Over the past 12 months, Ligand Pharmaceuticals paid a dividend of 15 USD . This corresponds to a dividend yield of about 14.26 %. For the coming 12 months, Ligand Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Ligand Pharmaceuticals?

The current dividend yield of Ligand Pharmaceuticals is 14.26 %.

When does Ligand Pharmaceuticals pay dividends?

Ligand Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Ligand Pharmaceuticals?

Ligand Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Ligand Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Ligand Pharmaceuticals located?

Ligand Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Ligand Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Ligand Pharmaceuticals from 4/19/2007 amounting to 2.5 USD, you needed to have the stock in your portfolio before the ex-date on 4/3/2007.

When did Ligand Pharmaceuticals pay the last dividend?

The last dividend was paid out on 4/19/2007.

What was the dividend of Ligand Pharmaceuticals in the year 2023?

In the year 2023, Ligand Pharmaceuticals distributed 0 USD as dividends.

In which currency does Ligand Pharmaceuticals pay out the dividend?

The dividends of Ligand Pharmaceuticals are distributed in USD.